Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the
development of revolutionary bone graft material and coatings for
medical applications, today announced that it has received a compliance
notice from the NYSE MKT compliance group.
Specifically the notice indicated that the Company is not in compliance
with Sections 1003(a)(iii) and 1003(a)(ii), regarding stockholder’s
equity of less than $6 million and net losses in five of its most recent
fiscal years and stockholders‘ equity of less than $4 million and net
losses in three of its four most recent fiscal years, respectively. The
Company will be required to submit a plan by June 13, 2013 to address
how it intends to regain compliance.
“The receipt of the letter does not have an immediate effect upon the
listing of the Company's common stock,” said John Gandolfo, Interim
Co-Chief Executive Officer and Chief Financial Officer of Bacterin
International. “We anticipated receiving this notice and have already
begun moving forward with a plan to resolve the matter and continue with
our listing on the NYSE MKT exchange. We feel we have a few options
available and will take the appropriate steps to address the situation.”
Pursuant to Exchange rules, the Company's stock will continue to be
listed for trading, and on or before June 13, 2013, the Company will
furnish the Exchange with a specific plan of how it will return to
compliance on or before November 13, 2014. If the Exchange accepts the
Plan, Bacterin will be able to continue its listing during the plan
period, but will be subject to continued periodic review by the Exchange
staff. If the Company does not make progress consistent with the Plan
during the Plan period, the Exchange could initiate delisting
proceedings.
The Company recently reported first quarter 2013 revenues of $8.6
million, which was a 11% increase over first quarter 2012 revenues and a
6% increase over reported revenues for the fourth quarter of 2012.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops,
manufactures and markets biologics products to domestic and
international markets. Bacterin's proprietary methods optimize the
growth factors in human allografts to create the ideal stem cell
scaffold to promote bone, subchondral repair and dermal growth. These
products are used in a variety of applications including enhancing
fusion in spine surgery, relief of back pain, promotion of bone growth
in foot and ankle surgery, promotion of cranial healing following
neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops and licenses coatings for
various medical device applications. For further information, please
visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to significant risks and
uncertainties. Forward-looking statements include statements that are
predictive in nature, that depend upon or refer to future events or
conditions, or that include words such as "continue," "efforts,"
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
"projects," "forecasts," "strategy," "will," "goal," "target,"
"prospects," "potential," "optimistic," "confident," "likely,"
"probable" or similar expressions or the negative thereof. Statements of
historical fact also may be deemed to be forward-looking statements. We
caution that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a
variety of important factors, including, among others: the Company's
ability to meet its existing and anticipated contractual obligations,
including financial covenant and other obligations contained in the
Company’s secured lending facility; the Company’s ability to manage cash
flow and achieve profitability; the Company's ability to develop,
market, sell and distribute desirable applications, products and
services and to protect its intellectual property; the ability of the
Company's sales force to achieve expected results; the ability of the
Company's customers to pay and the timeliness of such payments; the
Company's ability to obtain financing as and when needed; changes in
consumer demands and preferences; the Company's ability to attract and
retain management and employees with appropriate skills and expertise;
the Company’s ability to attract and retain a well qualified Chief
Executive Officer; the Company’s ability to successfully conclude
government investigations; the impact of changes in market, legal and
regulatory conditions and in the applicable business environment,
including actions of competitors; and other factors. Additional risk
factors are listed in the Company's Annual Report on Form 10-K and
Quarterly Report on Form 10-Q under the heading "Risk Factors." The
Company undertakes no obligation to release publicly any revisions to
any forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events,
except as required by law.
<div class="copyright">
Copyright Business Wire 2013
</div>